Myth: AAV is harmless — not always. Quick win: design trials with long oncogenicity monitoring and clear stopping rules to reduce holds and restore trust. Full breakdown → future.xsbrt.com/GeneTherapyRiskRegulatio... Replies/saves welcome. #AAV_gene_therapy

Andelyn Biosciences Collaborates with Tern Therapeutics to Tackle CLN2 Batten Disease with AAV Gene Therapy Andelyn Biosciences teams up with Tern Therapeutics for late-stage manufacturing of AAV gene therapy aimed at curing CLN2 Batten disease, offering hope for affected children.

Andelyn Biosciences Collaborates with Tern Therapeutics to Tackle CLN2 Batten Disease with AAV Gene Therapy #USA #Columbus #Andelyn_Biosciences #AAV_Gene_Therapy #CLN2_Batten_Disease

Viralgen Enters Clinical Development Network to Tackle Rare Diseases Viralgen partners with Orphan Therapeutics Accelerator to enhance AAV gene therapy efforts for ultra-rare diseases, aiming to streamline manufacturing processes.

Viralgen Enters Clinical Development Network to Tackle Rare Diseases #Spain #San_Sebastián #Viralgen #AAV_Gene_Therapy #Orphan_Therapeutics_Accelerator

Azenta Life Sciences and Form Bio Partner to Revolutionize Gene Therapy Development Azenta Life Sciences teams up with Form Bio to enhance AAV gene therapy, utilizing advanced sequencing and AI analysis for faster, safer solutions.

Azenta Life Sciences and Form Bio Partner to Revolutionize Gene Therapy Development #USA #Burlington #AAV_Gene_Therapy #Azenta_Life_Sciences #Form_Bio

Viralgen Partners with Trogenix to Propel AAV Gene Therapy for Glioblastoma Viralgen joins forces with Trogenix to advance AAV gene therapy for glioblastoma, enhancing manufacturing and accelerating clinical trials.

Viralgen Partners with Trogenix to Propel AAV Gene Therapy for Glioblastoma #Spain #San_Sebastián #Viralgen #AAV_Gene_Therapy #Trogenix

Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting Avirmax Biopharma is set to make a significant impact at the 2025 ARVO meeting with multiple presentations focused on ocular gene therapy advancements through its proprietary technologies.

Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting #Avirmax_Biopharma #AAV_Gene_Therapy #Dry_AMD